Tracheal Aspirate and Bronchoalveolar Lavage as Potential Specimen Types for COVID-19 Testing Using the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV

被引:8
|
作者
Kim, Sang Ho [1 ]
AlMutawa, Fatimah [2 ,3 ]
机构
[1] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[2] Western Univ, Dept Pathol & Lab Med, London, ON, Canada
[3] London Hlth Sci Ctr, London, ON, Canada
来源
MICROBIOLOGY SPECTRUM | 2022年 / 10卷 / 03期
关键词
SARS-CoV-2; multiplex; lower respiratory tract specimen; COVID-19; Xpert Xpress SARS-CoV-2 assay;
D O I
10.1128/spectrum.00399-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Xpert Xpress SARS-CoV-2/Flu/RSV is a rapid diagnostic test currently approved for the detection of SARS-CoV-2 using upper respiratory tract specimens. This study attempts to assess the performance of this assay using upper and lower respiratory tract specimens by comparing its results to the lab-developed PCR test. We assessed the performance of GeneXpert for the detection of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus for upper respiratory tract specimens. In addition, the SARS-CoV-2 detection was evaluated for lower respiratory tract specimens (bronchoalveolar lavage and tracheal aspirate). Precision and reproducibility of the test were also assessed using samples with varying cycle threshold values. Xpert Xpress SARS-CoV-2/Flu/RSV shows 100% positive and negative agreements for all four targets when tested using upper respiratory tract specimens. For lower respiratory tract specimens, tracheal aspirate and bronchoalveolar lavage samples respectively show 96% and 100% positive percent agreement for SARS-Cov-2 target only. No positive flu/RSV samples were included for lower respiratory tract specimens. Both samples show 100% negative percent agreement. The precision and reproducibility assay also showed 100% correspondence. Xpert Xpress SARS-CoV-2/Flu/RSV can be potentially used for SARS-Cov-2 detection in lower respiratory tract specimens. Performance passed our study acceptance criteria and shows promising implications as a point of care detection assay. IMPORTANCE Cepheid's Xpert Xpress SARS-CoV-2/Flu/RSV provides a means of rapid diagnosis that can help in hospital bed management and patient flow. It is also important for each microbiology lab to increase its capacity and most importantly have a different platform to overcome the anticipated reagent shortage at times of peak community transmission. There is limited evidence on using it for lower respiratory tract specimens. Here we present our validation for upper respiratory tract specimens as well as a potential use for lower respiratory specimens (BAL and TA), and we discuss some of the applications we have been using in our organization. Cepheid's Xpert Xpress SARS-CoV-2/Flu/RSV provides a means of rapid diagnosis that can help in hospital bed management and patient flow. It is also important for each microbiology lab to increase its capacity and most importantly have a different platform to overcome the anticipated reagent shortage at times of peak community transmission.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Ozone: A Potential Oxidant for COVID-19 Virus (SARS-CoV-2)
    Tizaoui, Chedly
    [J]. OZONE-SCIENCE & ENGINEERING, 2020, 42 (05) : 378 - 385
  • [32] SARS-COV-2 as potential microRNA sponge in COVID-19 patients
    Chang Li
    Rebecca Wang
    Aurora Wu
    Tina Yuan
    Kevin Song
    Yongsheng Bai
    Xiaoming Liu
    [J]. BMC Medical Genomics, 15
  • [33] Potential repurposed SARS-CoV-2 (COVID-19) infection drugs
    Abuo-Rahma, Gamal El-Din A.
    Mohamed, Mamdouh F. A.
    Ibrahim, Tarek S.
    Shoman, Mai E.
    Samir, Ebtihal
    Abd El-Baky, Rehab M.
    [J]. RSC ADVANCES, 2020, 10 (45) : 26895 - 26916
  • [34] Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)
    Verma, Surjeet
    Twilley, Danielle
    Esmear, Tenille
    Oosthuizen, Carel B.
    Reid, Anna-Mari
    Nel, Marize
    Lall, Namrita
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [35] Safe Elective Surgery Using Selective SARS-CoV-2 (COVID-19) Molecular Testing
    Ray, Hollis M.
    Kamitsuka, Paul F.
    Firetti, Pamela W.
    Almeter, Andrew L.
    McNabb, Kevin M.
    von Biberstein, S. Elizabeth
    Barton, Andrew C. H.
    Shakar, Robert
    Paul, J. West
    [J]. AMERICAN JOURNAL OF MEDICAL QUALITY, 2022, 37 (01) : 65 - 71
  • [36] Evaluation of potential COVID-19 recurrence in patients with late repeat positive SARS-CoV-2 testing
    Peltan, Ithan D.
    Beesley, Sarah J.
    Webb, Brandon J.
    Lopansri, Bert K.
    Sinclair, Will
    Jacobs, Jason R.
    Brown, Samuel M.
    [J]. PLOS ONE, 2021, 16 (05):
  • [37] Repeat laboratory testing of SARS-CoV-2 is necessary to diagnose COVID-19
    Zhuang, Guilong
    Ou, Xueting
    Zhou, Liyang
    Pan, Xingfei
    Li, Guohang
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (09) : 1164 - 1168
  • [38] Reducing COVID-19 quarantine with SARS-CoV-2 testing: a simulation study
    Peng, Bo
    Zhou, Wen
    Pettit, Rowland W.
    Yu, Patrick
    Matos, Peter G.
    Greninger, Alexander L.
    McCashin, Julie
    Amos, Christopher, I
    [J]. BMJ OPEN, 2021, 11 (07):
  • [39] SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
    Vogl, Thomas
    Leviatan, Sigal
    Segal, Eran
    [J]. CELL REPORTS MEDICINE, 2021, 2 (02)
  • [40] Disparities in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic
    Dryden-Peterson, Scott
    Velasquez, Gustavo E.
    Stopka, Thomas J.
    Davey, Sonya
    Lockman, Shahin
    Ojikutu, Bisola O.
    [J]. JAMA NETWORK OPEN, 2021, 4 (02) : E2037067